Study of ATI-1777 in Patients 12 to 65 Years Old With Moderate or Severe Atopic Dermatitis
Status:
Recruiting
Trial end date:
2023-04-06
Target enrollment:
Participant gender:
Summary
This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and
efficacy of ATI-1777 in patients 12 to 65 years old with moderate or severe Atopic
Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once
daily or twice daily for 4 weeks.